Biocon Executive Chair Kiran Mazumdar-Shaw said expiring biologic patents could help the company expand affordable cancer biosimilars and rise beyond its current top-five global ranking, while AI could shorten clinical trials by predicting safety…
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0